Literature DB >> 28739711

Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy.

Ryo Ariyasu1, Atsushi Horiike1, Takahiro Yoshizawa1, Yosuke Dotsu1, Junji Koyama1, Masafumi Saiki1, Tomoaki Sonoda1, Shingo Nishikawa1, Satoru Kitazono1, Noriko Yanagitani1, Makoto Nishio2.   

Abstract

BACKGROUND/AIM: Adrenal insufficiency is one of the adverse events (AEs) associated with anti-programmed death-1 (PD1) therapy. Delaying diagnoses can lead to serious conditions. It is necessary to elucidate detailed clinical features of these AEs. PATIENTS AND METHODS: Patients treated with anti-PD-1 monotherapy or in combination with anti-cytotoxic T cell lymphocyte-4 therapy at our hospital from January 2013 to December 2016 were identified. The patients' clinical characteristics and laboratory and radiologic findings were collected.
RESULTS: Adrenal insufficiency occurred in 3% of the patients. All patients were male. At the onset of symptoms, eosinophilia (>500/μl) was observed in four cases. Eosinophilia was observed more than a month before onset of symptoms in three cases. Other pituitary hormones remained relatively stable. Radiological evidence of pituitary inflammation was detected only in one case.
CONCLUSION: Most anti-PD1-related adrenal insufficiency cases involved an isolated ACTH deficiency. Eosinophilia may be an early indicator before the onset of symptoms. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Anti-PD-1; adrenal insufficiency; isolated ACTH deficiency; nivolumab; pembrolizumab

Mesh:

Substances:

Year:  2017        PMID: 28739711     DOI: 10.21873/anticanres.11814

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  13 in total

Review 1.  Toxicity of tumor immune checkpoint inhibitors-more attention should be paid.

Authors:  Yu Liu; Hao Wang; Juan Deng; Chenglong Sun; Yayi He; Caicun Zhou
Journal:  Transl Lung Cancer Res       Date:  2019-12

Review 2.  Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.

Authors:  Iosune Baraibar; Ignacio Melero; Mariano Ponz-Sarvise; Eduardo Castanon
Journal:  Drug Saf       Date:  2019-02       Impact factor: 5.606

3.  Thyrotoxicosis and Adrenocortical Hormone Deficiency During Immune-checkpoint Inhibitor Treatment for Malignant Melanoma.

Authors:  Hiroyuki Ariyasu; Hidefumi Inaba; Takayuki Ota; Hiroyuki Yamaoka; Yasushi Furukawa; Hiroshi Iwakura; Naotaka Doi; Yuki Yamamoto; Takashi Akamizu
Journal:  In Vivo       Date:  2018 Mar-Apr       Impact factor: 2.155

Review 4.  Isolated ACTH deficiency induced by cancer immunotherapy: a systematic review.

Authors:  Pedro Iglesias; Juan Cristóbal Sánchez; Juan José Díez
Journal:  Pituitary       Date:  2021-03-24       Impact factor: 4.107

5.  Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors.

Authors:  Tomoko Kobayashi; Shintaro Iwama; Daisuke Sugiyama; Yoshinori Yasuda; Takayuki Okuji; Masaaki Ito; Sachiko Ito; Mariko Sugiyama; Takeshi Onoue; Hiroshi Takagi; Daisuke Hagiwara; Yoshihiro Ito; Hidetaka Suga; Ryoichi Banno; Hiroyoshi Nishikawa; Hiroshi Arima
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

6.  Isolated ACTH deficiency during single-agent pembrolizumab for squamous cell lung carcinoma: a case report.

Authors:  Sho Tanaka; Masanori Abe; Masaru Kushimoto; Tsukasa Nishizawa; Masahiro Takubo; Kazutaka Mitsuke; Jin Ikeda; Midori Fujishiro; Katsuhiko Ogawa; Ichiro Tsujino; Yutaka Suzuki
Journal:  Clin Diabetes Endocrinol       Date:  2020-01-06

7.  Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH.

Authors:  M S Siddiqui; Z M Lai; L Spain; V Greener; S Turajlic; J Larkin; D L Morganstein
Journal:  J Endocrinol Invest       Date:  2020-05-24       Impact factor: 4.256

8.  Eosinophil counts can be a predictive marker of immune checkpoint inhibitor-induced secondary adrenal insufficiency: a retrospective cohort study.

Authors:  Shinobu Takayasu; Satoru Mizushiri; Yutaka Watanuki; Satoshi Yamagata; Mari Usutani; Yuki Nakada; Yuko Asari; Shingo Murasawa; Kazunori Kageyama; Makoto Daimon
Journal:  Sci Rep       Date:  2022-01-25       Impact factor: 4.379

Review 9.  Crosstalk between Dendritic Cells and Immune Modulatory Agents against Sepsis.

Authors:  Guoying Wang; Xianghui Li; Lei Zhang; Abualgasim Elgaili Abdalla; Tieshan Teng; Yanzhang Li
Journal:  Genes (Basel)       Date:  2020-03-18       Impact factor: 4.096

10.  Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer: A Case Series.

Authors:  Kei Sonehara; Kazunari Tateishi; Taisuke Araki; Masamichi Komatsu; Jumpei Akahane; Hiroshi Yamamoto; Masayuki Hanaoka
Journal:  Case Rep Oncol       Date:  2021-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.